Anthropic establishes biology lab to advance AI drug program

Alphabet: Alphabet is the parent company of Google and other technology businesses, including its drug discovery subsidiary Isomorphic Labs. The news references Isomorphic Labs' ongoing efforts to advance AI-driven drug candidates toward clinical stages, providing context for Anthropic's own preclinical ambitions in a competitive field. Novartis: Novartis is a global pharmaceutical company focused on developing and commercializing innovative medicines. Its CEO, Vas Narasimhan, was recently added to Anthropic's board, reflecting closer ties between the AI startup and established drugmakers as Anthropic expands its life sciences capabilities. Anthropic: Anthropic is an AI research company developing the Claude family of large language models with a focus on safe and beneficial artificial intelligence. In this news, it has established a physical wet lab in the San Francisco Bay Area to conduct real-world biology experiments beyond computer simulations, advancing its program to apply AI to drug discovery for rare and underserved diseases. The lab supports efforts to use Claude to direct robotic systems in automated lab work while maintaining human oversight. Eric Kauderer-Abrams: Eric Kauderer-Abrams serves as head of life sciences at Anthropic, overseeing the company's initiatives at the intersection of AI and biology. He confirmed in a recent interview that Anthropic is performing physical lab experiments typical of biotech firms, both in-house and with partners, to accelerate progress in life sciences without entering clinical trials. He emphasized the personal and company-wide mission to leverage powerful AI for medical breakthroughs that benefit the world. Lab Development: Anthropic has built a wet lab in the Bay Area to perform physical biology experiments and test AI-directed robotic automation in real lab settings. Strategic Focus: Anthropic is prioritizing preclinical work on conditions considered undruggable by traditional pharma, while deliberately avoiding clinical trials to prevent direct competition with drugmakers. AI Safety Balance: The company continues to advance life-sciences AI tools while addressing risks, including potential misuse for biological weapons and calls for responsible development slowdowns.